Marker Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 0.98 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 16.34M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.
Details
| Name | Marker Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 5 |
| Founded | 1999 |
| Ceo | Juan Vera |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US57055L2060 |
| Cusip | 57055L206 |
| Cik | 0001094038 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Juan F. Vera M.D. | Co-Founder, Chief Executive Officer, President, Treasurer, Secretary and Director |
| Elizabeth Donnelly | Director of Administration |
| Dr. Maria-Bernadette Madel Ph.D. | Director of Corporate Operations and External Communications |
| Edmund Cheung | Vice President of Human Resources |
| Patricia Allison | Head of Clinical Operations |
| Mary Newman Ph.D. | Head of Regulatory Affairs |
| Dr. Robert Z. Florkiewicz Sr., Ph.D. | Senior Director of Molecular Biology and Virology |
Contact
| Address | 2450 Holcombe Blvd, TMC Partners Office 1.311, Houston, Texas 77021, United States |
| Phone | 713 400 6400 |
| Website | https://markertherapeutics.com |